chang recommend chang price
downgrad valuat pt
home run us past year
multi-year out-performance downgrad share
rate pt tsr current
yin yang qualiti manag vs valuat without
doubt believ manag team one
best jay done busi
past year noth short remark
doubl margin oper tough end market
speak qualiti team said share
outperform peer bp ytd see valuat
fair current level given move
sidelin multi-year run
acceler vs price-to-earnings multipl think next leg
alpha tie revenu acceler med-tech p/e
highli correl organ top-line bax lrp
contempl constant currenc compound-annual-growth-rate
period acceler rang
period think outlook price
stock current level trade price-to-earnings
lacuna next month see revenu
inflect given price-to-earnings multipl like cap
next month form basi call
could wrong
upsid risk becom pain awar qualiti
manag team correl alpha gener
bet manag team biggest upsid
risk mind one could argu jay
roadmap plan continu surpris st
downsid risk medic deliveri miss last year
first hiccup seen
segment guid seem lay
mis-step factor outsid management control could
pressur multipl
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
valuat methodolog base mix discount cash flow analysi rel valuat multipl
increas competit price pressur fluid system fda qualiti issu tax reform uncertainti inabl
articl articl
time dissemin april
analyst william tong alina levchuk vijay kumar primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research
